Critical Determinants of Cardiovascular Risk in Rheumatoid Arthritis
Keywords: ATM-p53; Akt; Apaf 1; Atheroslerosis; BT-474; Bax; Bcl-2 family; Bcl-2 pathways; Caiazzana and Ravece; Confocal micros-copy analysis; HL60 (human promyelocytic leukemia cells); HT-29 cells; Her-2/neu; Her2/neu on-cogene; Hydroxytyrosol (3,4 DHPEA-EDA); MAPK pathway; Olea Euopaea; PI-3 kinase/Akt pathway; Ras farnesylation; SK-Br3 cells; apoptosome; cardiovascular risk factors; caspases; cellular proliferation; cholesterol biosynthesis; chronic inflammation; colorectal can-cer cell lines; cytochrome; cytosolic proteins; differentiation; erythrodiol; human cancers; hydroxytyrosol; metastasis; mo-tility; necrotic cells; oleocanthal; p185 Her-2/neu oncoprotein; pathogenesis; pentacyclic triterpenic acids; pinoresinol; poly-ADP-ribose polym-erase; reactive oxygen species; rheumatoid arthritis; skin carcinogenesis; squalene; transformation; trastuzumab (Her-ceptinTM); trol of the G2/M checkpoint, p53 is directly controlled by the ATM-ATR genes; tyrosol
Document Type: Research Article
Publication date: 01 January 2011
- Current Pharmaceutical Design publishes timely in-depth reviews covering all aspects of current research in rational drug design. Each issue is devoted to a single major therapeutic area. A Guest Editor who is an acknowledged authority in a therapeutic field has solicits for each issue comprehensive and timely reviews from leading researchers in the pharmaceutical industry and academia.
Each thematic issue of Current Pharmaceutical Design covers all subject areas of major importance to modern drug design, including: medicinal chemistry, pharmacology, drug targets and disease mechanism. - Editorial Board
- Information for Authors
- Subscribe to this Title
- Ingenta Connect is not responsible for the content or availability of external websites
- Access Key
- Free content
- Partial Free content
- New content
- Open access content
- Partial Open access content
- Subscribed content
- Partial Subscribed content
- Free trial content